2022
Clinical implications of Type 2 diabetes on outcomes after cardiac transplantation
Chouairi F, Mullan C, Ahmed A, Bhinder J, Guha A, Miller P, Jastreboff A, Fuery M, Chiravuri M, Geirsson A, Desai N, Maulion C, Sen S, Ahmad T, Anwer M. Clinical implications of Type 2 diabetes on outcomes after cardiac transplantation. PLOS ONE 2022, 17: e0273111. PMID: 36516178, PMCID: PMC9750001, DOI: 10.1371/journal.pone.0273111.Peer-Reviewed Original ResearchConceptsPost-transplant mortalityType 2 diabetesAllocation system changeOld allocation systemsHeart transplant recipientsOutcomes of patientsOrgan Sharing databaseProportion of patientsHeart transplantation outcomesLower likelihoodLikelihood of transplantationHigher likelihoodNew allocation systemCardiac transplantationHeart transplantationTransplant recipientsT2D patientsHeart failureSharing databaseCox regressionTransplantation outcomesUnited NetworkWorse outcomesT2DPatients
2020
1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States
REIFSNIDER O, PIMPLE P, STARGARDTER M, BRAND S, DESAI N, SHETTY S. 1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States. Diabetes 2020, 69 DOI: 10.2337/db20-1158-p.Peer-Reviewed Original ResearchBoehringer Ingelheim PharmaceuticalsUse of empagliflozinT2D patientsCardiovascular diseaseAdverse eventsUnited Kingdom Prospective Diabetes Study (UKPDS) risk equationsGLP-1 receptor agonistsT2D-related complicationsSecond-line therapyType 2 diabetesClinical trial resultsTreatment-induced changesBackground metforminCVD subgroupsCV deathRenal outcomesHazard ratioClinical outcomesSGLT2 inhibitorsCVS CaremarkMyocardial infarctionReceptor agonistSpouse/partnerImproved outcomesDrug classes